[The role of adjuvant chemotherapy with S-1 for gastric cancer patients].
A randomized controlled trial of adjuvant chemotherapy with S-1 for gastric cancer (ACTS-GC) demonstrated that the chemotherapy with S-1 improved the relapse-free survival and overall survival rates of patients with locally advanced gastric cancer. We examined retrospectively 47 patients with locally advanced gastric cancer, who received adjuvant chemotherapy with S-1 after curative gastrectomy. Patients who received more than 50% of the total scheduled dose of S-1 during the first 1 year after starting the chemotherapy showed a tendency to favorable outcome in terms of relapse-free survival compared with patients who received less than 50% of the dose, although no statistical significance was detected. Age did not show a significant correlation with tolerability. The number of elderly people with gastric cancer will increase in the next decade. They should be candidates for adjuvant chemotherapy on the basis of a geriatric assessment.
Kitagawa
Maki
M
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine.
Ichikawa
Daisuke
D
Okamoto
Kazuma
K
Shiozaki
Atsushi
A
Fujiwara
Hitoshi
H
Kuriu
Yoshiaki
Y
Ikoma
Hisashi
H
Nakanishi
Masayoshi
M
Ochiai
Toshiya
T
Sakakura
Chohei
C
Kokuba
Yukihito
Y
Sonoyama
Teruhisa
T
Otsuji
Eigo
E
D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D006801:Humans; D010094:Oxonic Acid / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use*
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid